Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

Andrew L. Pecora, MD
Published: Wednesday, Jan 03, 2018



Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The rationale behind this combination is that CTLA-4 inhibitors are a true suppressor of T-regulatory cells. Additionally, CTLA-4 works centrally, whereas PD-1 works in the periphery, which makes this an ideal combination, explains Pecora.
 
SELECTED
LANGUAGE


Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The rationale behind this combination is that CTLA-4 inhibitors are a true suppressor of T-regulatory cells. Additionally, CTLA-4 works centrally, whereas PD-1 works in the periphery, which makes this an ideal combination, explains Pecora.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x